EBV Microorganismos Terapêutica

Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention

Escrito por Carla Brito Lopes

Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.
At a meeting held at the U.S. National Institutes of Health (NIH) on 1 February 2011, scientists from government, academia, and industry (1) assembled to discuss the merits of a vaccine for Epstein-Barr virus (EBV) and the opportunities and challenges for its development. Here, we highlight relevant clinical and epidemiological data and make recommendations for future EBV vaccine research and development.

Get the full article here: http://stm.sciencemag.org/content/3/107/107fs7.full.pdf


From: [J. I. Cohen, A. S. Fauci, H. Varmus, G. J. Nabel, Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention. Sci. Transl. Med. 3, 107fs7 (2011).]. Reprinted with permission from AAAS.

Sobre o autor

Carla Brito Lopes

Carla nasceu a 14 de Fevereiro de 1977 em Viana do Castelo. Completou o bacharelato em Anatomia Patológica, Citológica e Tanatológica na ESTES-Porto em 1998 e licenciou-se em 2001 pela Escola Superior de Tecnologia da Saúde em Lisboa. Concluiu a certificação em Laboratory Management pela ASCP (American Association of Clinical Pathology) em Setembro de 2016.
Actualmente encontra-se a frequentar mestrado em Genética Molecular e Biomedicina na Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa.